204 related articles for article (PubMed ID: 2652614)
1. Aggressive needle biopsy protocol prevents loss of renal allografts to undetected rejection during early posttransplant dysfunction.
Thistlethwaite JR; Woodle ES; Mayes JT; Stuart JK; Heffron TG; Spargo BH; Stuart FP
Transplant Proc; 1989 Feb; 21(1 Pt 2):1890-2. PubMed ID: 2652614
[No Abstract] [Full Text] [Related]
2. Triple immunosuppressive therapy in immunologic high-risk renal allograft recipients.
Cole E; Robinson C; Bear R
Transplant Proc; 1989 Feb; 21(1 Pt 2):2026-7. PubMed ID: 2652662
[No Abstract] [Full Text] [Related]
3. Conversion to triple therapy in renal allograft patients with renal dysfunction and chronic interstitial lesions or vascular lesions on renal biopsy.
Leaker B; Neild GH; Rudge C; Mansell M; Thompson FD
Transplant Proc; 1989 Feb; 21(1 Pt 2):1548-9. PubMed ID: 2652501
[No Abstract] [Full Text] [Related]
4. Effect of duration of MALG therapy in a quadruple immunosuppressive protocol.
Stratta RJ; D'Alessandro AM; Armbrust MJ; Pirsch JD; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1989 Feb; 21(1 Pt 2):1726-8. PubMed ID: 2652564
[No Abstract] [Full Text] [Related]
5. Quadruple drug therapy prevents graft loss from acute rejection without increasing mortality.
Light JA; Aquino A; Ali A; Rodriguez R; Ali S
Transplant Proc; 1987 Feb; 19(1 Pt 3):1927-30. PubMed ID: 3547897
[No Abstract] [Full Text] [Related]
6. Quadruple therapy for cadaver renal transplantation.
Deierhoi MH; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1987 Feb; 19(1 Pt 3):1917-9. PubMed ID: 3274452
[No Abstract] [Full Text] [Related]
7. Effect of discontinuing or restricting cyclosporine on late renal allograft rejection and function.
Woodle ES; Heffron TG; Stuart JK; Thistlethwaite JR; Stuart FP
Transplant Proc; 1989 Feb; 21(1 Pt 2):1641-2. PubMed ID: 2652536
[No Abstract] [Full Text] [Related]
8. Pediatric renal transplantation results are improved with triple drug therapy with cyclosporine, azathioprine, and prednisone.
MacDonell RC; Johnson K; Richie R; Nylander W; McMahon Y; Niblack G; Green W; Morrissey J; Ynares C
Transplant Proc; 1989 Feb; 21(1 Pt 2):1701-4. PubMed ID: 2652557
[No Abstract] [Full Text] [Related]
9. Control of rejection of transplanted organs.
Keown PA; Stiller CR
Adv Intern Med; 1986; 31():17-46. PubMed ID: 3511616
[No Abstract] [Full Text] [Related]
10. Definition, diagnosis, and management of rejection in the second to sixth months posttransplant--an overview.
Matas AJ; Tellis VA; Quinn T; Soberman R; Veith FJ
Transplant Proc; 1986 Apr; 18(2 Suppl 1):141-50. PubMed ID: 3515682
[TBL] [Abstract][Full Text] [Related]
11. An immunosuppressive protocol compatible with the United States kidney transplant diagnosis related grouping.
Stuart FP; Stuart JK; Thistlethwaite JR; Gaber AO; Mayes J
Transplant Proc; 1987 Feb; 19(1 Pt 3):1959-60. PubMed ID: 3152656
[No Abstract] [Full Text] [Related]
12. Early graft function in primary and regraft recipients of paired cadaveric kidneys.
Jaklitsch MT; Deierhoi MH; Hudson S; Barber WH; Barger BO; Phillips MG; Diethelm AG
Transplant Proc; 1989 Feb; 21(1 Pt 2):1274-5. PubMed ID: 2652421
[No Abstract] [Full Text] [Related]
13. The role of antilymphocyte globulin in cadaver renal transplantation.
Novick AC
Transplant Proc; 1986 Jun; 18(3 Suppl 2):22-7. PubMed ID: 3521000
[No Abstract] [Full Text] [Related]
14. Dallas experience with cyclosporine A (CsA) one to six months posttransplant.
Hull AR; Atkins CR; Brinker KR; Dawidson I; Dickerman RM; Emerson W; Helderman JH; Levitz B; Long DL; Nesser D
Transplant Proc; 1986 Apr; 18(2 Suppl 1):128-31. PubMed ID: 3515679
[No Abstract] [Full Text] [Related]
15. Cox regression analysis of outcome risk factors in 519 renal allograft recipients.
Canafax DM; Savik SK; Draxler CA; Le CT; Ascher NL; Payne WD; Sutherland DE; Migliori RJ; Simmons RL; Najarian JS
Transplant Proc; 1987 Feb; 19(1 Pt 3):1947-8. PubMed ID: 3274455
[No Abstract] [Full Text] [Related]
16. Cyclosporine-steroids versus conventional therapy in cadaver kidney transplantation: analysis of a randomized trial at two years.
Gianello P; Squifflet JP; Pirson Y; Stoffel M; Dereme T; Alexandre GP
Transplant Proc; 1987 Feb; 19(1 Pt 3):1867-72. PubMed ID: 3547891
[No Abstract] [Full Text] [Related]
17. Use of OKT3 in kidney, pancreas, and liver transplantation.
D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
[No Abstract] [Full Text] [Related]
18. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
19. Primary dysfunction of renal allografts as a risk factor.
Margreiter R; Bösmüller C; Spielberger M; Königsrainer A; Dünser M
Transplant Proc; 1990 Aug; 22(4):1373-4. PubMed ID: 2389333
[No Abstract] [Full Text] [Related]
20. Quadruple drug induction treatment in patients with ATN-kidneys: expensive but effective.
Schilling M; Schleibner S; Abendroth D; Illner WD; Schneeberger H; Land W
Transplant Proc; 1990 Oct; 22(5):2283. PubMed ID: 2219369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
